Cargando…

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma

Severe eosinophilic asthma (SEA) is associated with high peripheral blood and airway eosinophilia, recurrent disease exacerbations and severe airflow limitation. Eosinophilic inflammation is also responsible for small airway disease (SAD) development. SEA patients experience poor disease control and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maglio, Angelantonio, Vitale, Carolina, Pellegrino, Simona, Calabrese, Cecilia, D’Amato, Maria, Molino, Antonio, Pelaia, Corrado, Triggiani, Massimo, Pelaia, Girolamo, Stellato, Cristiana, Vatrella, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615088/ https://www.ncbi.nlm.nih.gov/pubmed/34829778 http://dx.doi.org/10.3390/biomedicines9111550

Ejemplares similares

Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
por: Vitale, Carolina, et al.
Publicado: (2023)

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
por: Vatrella, Alessandro, et al.
Publicado: (2022)

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study
por: Maglio, Angelantonio, et al.
Publicado: (2023)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Novel Biological Therapies for Severe Asthma Endotypes
por: Pelaia, Corrado, et al.
Publicado: (2022)

Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2023)

Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
por: Pelaia, Corrado, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
por: Pelaia, Corrado, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Application of Proteomics and Peptidomics to COPD
por: Pelaia, Girolamo, et al.
Publicado: (2014)

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications
por: Pelaia, Corrado, et al.
Publicado: (2020)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Fractional exhaled nitric oxide and forced expiratory flow between 25% and 75% of vital capacity in children with controlled asthma
por: Yoon, Ji-Yong, et al.
Publicado: (2012)

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
por: Pelaia, Corrado, et al.
Publicado: (2021)

Predicted values for the forced expiratory flow adjusted for forced vital capacity, a descriptive study
por: Cox, Claire A., et al.
Publicado: (2020)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
por: Pelaia, Girolamo, et al.
Publicado: (2015)

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

The association of forced expiratory volume in one second and forced expiratory flow at 50% of the vital capacity, peak expiratory flow parameters, and blood eosinophil counts in exercise-induced bronchospasm in children with mild asthma
por: Akar, H. Haluk, et al.
Publicado: (2015)

Does DNA methylation mediate the association of age at puberty with forced vital capacity or forced expiratory volume in 1 s?
por: Li, Liang, et al.
Publicado: (2022)

Differences in clinical significance of bronchodilator responses measured by forced expiratory volume in 1 second and forced vital capacity
por: Choi, Joon Young, et al.
Publicado: (2023)

Reference Values of Forced Vital Capacity and Expiratory Flow in High-Level Cyclists
por: Dauty, Marc, et al.
Publicado: (2021)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
por: Pelaia, Corrado, et al.
Publicado: (2023)

Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test
por: Hankinson, John L., et al.
Publicado: (2014)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Clinical significance of low forced expiratory flow between 25% and 75% of vital capacity following treated pulmonary tuberculosis: a cross-sectional study
por: Pefura-Yone, Eric Walter, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jcmq9torkhtafc9vbobrnvnm4f